NJ Trim Clinic: Telehealth GLP-1 Weight Loss for All of New Jersey — $149/Month
Published by New Jersey Trim Clinic · Updated 2025-05-12
NJ Trim Clinic — Statewide Telehealth Medical Weight Loss
Looking for a trim clinic in NJ? New Jersey Trim Clinic is a physician-supervised telehealth medical weight loss program serving every county in New Jersey. Whether you are searching for "NJ trim clinic," "New Jersey trim clinic," "trim clinic NJ," or "trim clinic near me" — you have found a provider built for the way New Jersey lives.
No office visits. No waiting rooms. No Parkway traffic. Just a licensed physician, an evidence-based GLP-1 program, and medication shipped to your door.
What Makes This NJ Trim Clinic Different
New Jersey Trim Clinic was designed from the ground up as a telehealth-first program. That means every patient — whether you are in Bergen County, Mercer County, Atlantic County, or anywhere in between — gets the same level of physician-supervised care without leaving home.
Our programs include:
- Semaglutide (the active ingredient in Ozempic and Wegovy) — $149/month all-inclusive
- Tirzepatide (the active ingredient in Mounjaro and Zepbound) — $169/month all-inclusive
- NAD+ Therapy — Promotional pricing: $189 per treatment
- Physician consultations via secure telehealth
- Medication sourced from licensed U.S. pharmacies
- No membership fees, no hidden costs, no dose escalation charges
Serving All 21 Counties in New Jersey
Unlike clinics limited to a single office location, New Jersey Trim Clinic serves the entire state:
North Jersey: Bergen County, Passaic County, Hudson County, Essex County, Morris County, Sussex County, Warren County
Central Jersey: Middlesex County, Somerset County, Mercer County, Hunterdon County, Union County, Monmouth County
South Jersey: Atlantic County, Cape May County, Cumberland County, Salem County, Gloucester County, Camden County, Burlington County, Ocean County
Plus telehealth coverage extending into New York, Connecticut, and Pennsylvania.
Why New Jersey Patients Choose Telehealth
New Jersey is the most densely populated state in the country. Between commuting, work, family, and everything else, adding a drive to a clinic — and sitting in a waiting room — is the last thing most people want to do.
With New Jersey Trim Clinic's telehealth model:
- Your initial consultation happens from your couch, your office, or wherever you are
- Follow-up appointments are the same — quick, convenient, no travel
- Medication ships directly to your home
- Your physician monitors your progress remotely
It is medical weight loss designed for how New Jersey actually works.
$149/Month — The Most Affordable Trim Clinic in NJ
At $149 per month all-inclusive, New Jersey Trim Clinic is one of the most affordable physician-supervised GLP-1 programs available in the state. That price includes your medication, physician supervision, and ongoing telehealth consultations. There are no surprise fees — ever.
For perspective: that is about $5 a day. Less than a cup of coffee at most NJ cafes. Less than a single slice of pizza in some towns. It is a small daily investment in your long-term health.
How to Get Started
1. Book a free consultation — no obligation, no pressure
2. Speak with a licensed physician via secure telehealth
3. Receive your personalized treatment plan — if approved, medication ships to your door
4. Ongoing support — regular telehealth check-ins with your physician
About New Jersey Trim Clinic
New Jersey Trim Clinic combines experienced clinical expertise with the convenience of telehealth. We are committed to transparent pricing, physician-supervised care, and making medical weight loss accessible to all New Jersey residents.
Whether you found us by searching "NJ trim clinic," "trim clinic New Jersey," "semaglutide NJ," or "weight loss clinic near me" — welcome. We are here to help.
*Individual results vary. Treatment is only prescribed after evaluation by a licensed medical provider. No specific amount of weight loss is guaranteed. All medications sourced from licensed U.S. pharmacies.*
MEDICAL SOURCES & FURTHER READING
Read the source alongside the specific topic it supports. These independent sources do not endorse New Jersey Trim Clinic. Research findings are not a prediction of your results.
- NIH/NIDDK — Prescription Medications to Treat Overweight & Obesity
Supports: Weight-management medication requires individualized prescribing; eligibility, benefits, risks and ongoing treatment should be discussed with a healthcare professional. Nutrition and physical activity remain part of treatment.
- Mayo Clinic — Prescription weight-loss drugs
Supports: Prescription weight-loss medicines have eligibility restrictions, potential side effects and a need for professional oversight; they are used alongside lifestyle measures.
- Cleveland Clinic — GLP-1 Agonists
Supports: GLP-1 receptor agonists act on appetite and satiety, help regulate blood glucose and can slow stomach emptying. Common adverse effects include nausea, vomiting and diarrhea.
Evidence limits: The extent and duration of effects differ by drug, dose and individual; a general mechanism does not establish a guaranteed response.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
Supports: Semaglutide 2.4 mg plus lifestyle intervention produced weight loss in the STEP 1 randomized trial; gastrointestinal adverse events were reported.
Evidence limits: The main trial reported mean weight change of −14.9% at 68 weeks. This is not a predicted clinic outcome or proof that every semaglutide formulation has the same results.
- FDA — Wegovy (semaglutide) prescribing information
Supports: The approved product's label describes contraindications including personal or family history of medullary thyroid carcinoma and MEN 2, dose escalation, pregnancy considerations, gastrointestinal reactions, and warnings including pancreatitis, gallbladder disease and kidney injury due to volume depletion.
Evidence limits: This label is for Wegovy, not approval of New Jersey Trim Clinic or a compounded formulation. Individual prescribing decisions require a licensed provider.
- Tirzepatide Once Weekly for the Treatment of Obesity
Supports: The SURMOUNT-1 trial studied tirzepatide at different doses in adults with obesity or overweight without diabetes and reported weight reduction and gastrointestinal adverse events.
Evidence limits: SURMOUNT-1 was placebo-controlled, not a head-to-head comparison with semaglutide. Results do not establish guaranteed outcomes or equivalence of compounded medicines.
- FDA — Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
Supports: Compounded GLP-1 drugs are not FDA-approved. FDA describes dosing, quality, storage and other safety concerns, and advises that compounded drugs should only be used when a patient's medical needs cannot be met by an FDA-approved drug.
Evidence limits: Pharmacy registration is not FDA approval of a compounded product. Clinical trials of approved drugs do not establish the safety or effectiveness of compounded formulations.
- A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD
Supports: This exploratory pilot measured NAD+ and related metabolites during and after an intravenous infusion.
Evidence limits: It did not establish anti-aging, longevity, improved energy, cognition or clinical benefit, and did not study the clinic's injection regimen. A biological role for NAD+ does not prove a treatment benefit.
RESEARCH & REFERENCES
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding JPH, Batterham RL, Calanna S, et al.; STEP 1 Study Group. New England Journal of Medicine. 2021.
Research published in the New England Journal of Medicine reported greater weight reduction with semaglutide 2.4 mg plus lifestyle intervention than placebo in the studied adults without diabetes.
- Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, Aronne LJ, Ahmad NN, et al.; SURMOUNT-1 Investigators. New England Journal of Medicine. 2022.
Research published in the New England Journal of Medicine reported dose-dependent weight reduction with tirzepatide versus placebo over 72 weeks in the studied population.
- A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD
Grant R, Berg J, Mestayer R, Braidy N, Bennett J, Broom S, Watson J. Frontiers in Aging Neuroscience. 2019.
Research published in Frontiers in Aging Neuroscience reported changes in plasma and urinary metabolites during an NAD+ infusion pilot, not evidence of improved longevity or anti-aging outcomes.
General education is not individualized medical advice. Prescription treatment requires evaluation by a licensed provider. Eligibility, medication and dosing depend on individual circumstances.
Compounded drugs are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness or quality before marketing. Compounded drugs should only be used when a patient's medical needs cannot be met by an FDA-approved drug. Published studies of approved medications do not establish equivalent safety or effectiveness of compounded products.